Assessment of Macrophage Activation syndromE in STill's Disease

a study on Macrophage Activation Syndrome Still's Disease, Adult-Onset Stills Disease, Juvenile-Onset Arthritis

Summary

Eligibility
for people ages 6 months to 80 years (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics

Official Title

Assessment of Macrophage Activation syndromE in STill's Disease: Retrospective Chart Analysis of Patient HistorY, Symptom Resolution and Treatment Characteristics

Details

This is an observational, retrospective cohort study on the treatment utilization and outcomes of Macrophage Activation Syndrome (MAS) refractory to glucocorticoids (GC) in patients with Still's disease. The study will be conducted entirely through medical chart abstraction; all data will be taken from the patient's medical record, with no additional assessments.

Keywords

Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset, Juvenile Arthritis, Adult-Onset Still's Disease, Syndrome, Chart review

Eligibility

You can join if…

Open to people ages 6 months to 80 years

  • Age >6 months and ≤80 years at the beginning of the index MAS episode.
  • Diagnosis of Still's disease (sJIA (systemic Juvenile Idiopathic Arthritis) or AOSD (Adult Onset Stills Disease) diagnosis).
  • Diagnosis of MAS according to treating physician in the medical record.
  • Patients who have received at least 3 consecutive days of GC after diagnosis of MAS and/or are judged by the Investigator to be refractory to GC due to clinical worsening of patient's condition .
  • The onset of the index MAS episode occurred between 01 January 2012 and 30 September

You CAN'T join if...

  • A diagnosis of primary Hemophagocytic Lymphohistiocytosis (HLH) prior to the beginning of the index MAS episode.
  • Confirmed malignancy prior to the beginning of the index MAS episode.
  • Patient treated with any investigational product as a part of clinical trial during the index MAS episode.

Locations

  • Swedish Orphan Biovitrum Research Site accepting new patients
    Los Angeles California 90095 United States
  • Swedish Orphan Biovitrum Research Site accepting new patients
    Calgary Canada

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Swedish Orphan Biovitrum
ID
NCT06405152
Study Type
Observational
Participants
Expecting 80 study participants
Last Updated